[go: up one dir, main page]

AU2001239510A1 - Treatment of renal disorders - Google Patents

Treatment of renal disorders

Info

Publication number
AU2001239510A1
AU2001239510A1 AU2001239510A AU3951001A AU2001239510A1 AU 2001239510 A1 AU2001239510 A1 AU 2001239510A1 AU 2001239510 A AU2001239510 A AU 2001239510A AU 3951001 A AU3951001 A AU 3951001A AU 2001239510 A1 AU2001239510 A1 AU 2001239510A1
Authority
AU
Australia
Prior art keywords
treatment
renal disorders
renal
disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001239510A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of AU2001239510A1 publication Critical patent/AU2001239510A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2068—Compounds of unknown constitution, e.g. material from plants or animals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2001239510A 2000-04-04 2001-03-28 Treatment of renal disorders Abandoned AU2001239510A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0008332 2000-04-04
GBGB0008332.9A GB0008332D0 (en) 2000-04-04 2000-04-04 Treament
PCT/IB2001/000518 WO2001074390A2 (en) 2000-04-04 2001-03-28 The use of a calcium channel blocker for treating renal disorders

Publications (1)

Publication Number Publication Date
AU2001239510A1 true AU2001239510A1 (en) 2001-10-15

Family

ID=9889228

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2001239510A Abandoned AU2001239510A1 (en) 2000-04-04 2001-03-28 Treatment of renal disorders

Country Status (12)

Country Link
EP (1) EP1284719A2 (en)
JP (1) JP2003528927A (en)
AR (1) AR027763A1 (en)
AU (1) AU2001239510A1 (en)
BR (1) BR0109783A (en)
CA (1) CA2403950A1 (en)
GB (1) GB0008332D0 (en)
MX (1) MXPA02009819A (en)
PA (1) PA8514601A1 (en)
PE (1) PE20011163A1 (en)
TN (1) TNSN01051A1 (en)
WO (1) WO2001074390A2 (en)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT5874U1 (en) * 2000-12-29 2003-01-27 Bioorg Bv PHARMACEUTICAL PREPARATIONS CONTAINING AMLODIPINMALEAT
EP1345901A2 (en) * 2000-12-29 2003-09-24 Bioorganics B.V. Process for making amlodipine, derivatives thereof, and precursors therefor
US7335380B2 (en) 2000-12-29 2008-02-26 Synthon Ip Inc. Amlodipine free base
PT1443917E (en) * 2001-11-07 2006-06-30 Synthon Bv TAMSULOSIN TABLETS
NL1019882C2 (en) * 2002-02-01 2003-08-04 Synthon Licensing Pharmaceutical tablet composition useful for treating or preventing hypertension, angina or congestive heart failure comprises amlodipine free base
CO5400144A1 (en) 2002-03-11 2004-05-31 Novartis Ag ORGANIC COMPOUNDS
EP1551456A4 (en) 2002-09-30 2007-08-22 Kowa Co PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING RENAL DISEASES
PL377344A1 (en) 2003-01-31 2006-01-23 Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
US20080268049A1 (en) * 2005-02-11 2008-10-30 Dhaliwal Mona Stable Solid Dosage Forms of Amlodipine and Benazepril
BRPI0607791A2 (en) 2005-03-15 2010-03-23 Lupin Ltd Amlodipine and benazepril pharmaceutical compositions
BRPI0611024A2 (en) * 2005-04-29 2010-11-09 Hills Pet Nutrition Inc method for extending feline life, for delaying the onset of feline renal failure and for reducing morbidity and mortality from feline kidney disease, kit and means for communicating information or instructions related to the use of a diet having reduced levels of protein, phosphorus and sodium
CN108778334A (en) * 2016-03-24 2018-11-09 第三共株式会社 Drug for treating kidney trouble

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8710493D0 (en) * 1987-05-02 1987-06-03 Pfizer Ltd Dihydropyridines
DK0459666T3 (en) * 1990-05-31 1994-12-05 Pfizer Medicines for impotence
NZ242724A (en) * 1991-05-15 1994-09-27 Du Pont Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker
EP1013275A3 (en) * 1991-11-26 2001-01-10 Sepracor, Inc. Method and compositions for treating hypertension, angina and other disorders using optically pure (-) amlodipine
WO1996028185A2 (en) * 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
EP0795327A1 (en) * 1996-03-13 1997-09-17 Pfizer Inc. Use of Amlodipine for the treatment and prophylaxis of congestive cardiac failure of non-ischaemic origin

Also Published As

Publication number Publication date
GB0008332D0 (en) 2000-05-24
BR0109783A (en) 2003-01-21
CA2403950A1 (en) 2001-10-11
WO2001074390A2 (en) 2001-10-11
PA8514601A1 (en) 2002-08-26
WO2001074390A3 (en) 2002-05-30
AR027763A1 (en) 2003-04-09
PE20011163A1 (en) 2001-11-12
JP2003528927A (en) 2003-09-30
MXPA02009819A (en) 2003-03-27
EP1284719A2 (en) 2003-02-26
TNSN01051A1 (en) 2005-11-10

Similar Documents

Publication Publication Date Title
GB0007193D0 (en) Treatment of movrmrnt disorders
AU2002223827A1 (en) Well treatment
AU2002222853A1 (en) Therapeutic compounds
AU2001260513A1 (en) Microcapsule well treatment
AUPQ958400A0 (en) Validation of transactions
AU2002324201A1 (en) Waste treatment
AUPR074500A0 (en) Treatment of t cell disorders
AU2002231206A1 (en) Treatment of depression
AU2001239510A1 (en) Treatment of renal disorders
AU1356201A (en) Treatment of hyperproliferative disorders
IL143366A0 (en) Treatment of renal fibrosis
AU2001285667A1 (en) Sanitary cigarette case
AU3899100A (en) Treatment of hyperactivity disorders
AU2080201A (en) Treatment of addiction disorders
AU2001261324A1 (en) Psoriasis treatment
AU2002364774A1 (en) Ilk inhibitors for the treatment of renal disease
AU2001253560A1 (en) Methods of treatment
AU3582101A (en) The treatment of functional gastrointestinal disorders
AUPQ790900A0 (en) Treatment for scrubber effulent
AU2001272649A1 (en) Treatment of movement disorders
HK1058307A (en) Treatment of t cell disorders
AUPR078200A0 (en) Treatment of t cell disorders
AU3579101A (en) Waste treatment
HK1056502A (en) Methods of treatment
AUPR085100A0 (en) Novel therapy for hyperlipidaemia-associated disorders